Syntara (ASX:SNT) EBIT per Share : A$-0.02 (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara EBIT per Share?

Syntara's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 10.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Syntara's EBIT per Share or its related term are showing as below:

ASX:SNT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -72.2 Med: 5.4 Max: 25.8
Current: 10.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Syntara was 25.80% per year. The lowest was -72.20% per year. And the median was 5.40% per year.

ASX:SNT's 3-Year EBIT Growth Rate is ranked better than
54.2% of 845 companies
in the Drug Manufacturers industry
Industry Median: 7.3 vs ASX:SNT: 10.30

Syntara's EBIT for the six months ended in Dec. 2023 was A$-7.43 Mil.

Syntara EBIT per Share Historical Data

The historical data trend for Syntara's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara EBIT per Share Chart

Syntara Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT per Share

Get a 7-Day Free Trial

-0.05

-0.01

-0.03

-0.02

-0.01

Syntara Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Syntara EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Syntara's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.137	/	655.624
=	-0.02

Syntara's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.428	/	726.799
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

Syntara (ASX:SNT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Syntara EBIT per Share Related Terms

Thank you for viewing the detailed overview of Syntara's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.